Barriers to Insulin Initiation The Translating Research Into Action for Diabetes Insulin Starts Project by Karter, Andrew J. et al.
Barriers to Insulin Initiation
The Translating Research Into Action for Diabetes Insulin Starts Project
ANDREW J. KARTER, PHD1,2
USHA SUBRAMANIAN, MD, MS3
CHANDAN SAHA, PHD4
JESSE C. CROSSON, PHD5
MELISSA M. PARKER, MS1
BIX E. SWAIN, MS1
HOWARD H. MOFFET, MPH1
DAVID G. MARRERO, PHD6
OBJECTIVE— Reasons for failing to initiate prescribed insulin (primary nonadherence) are
poorly understood. We investigated barriers to insulin initiation following a new prescription.
RESEARCH DESIGN AND METHODS— We surveyed insulin-naïve patients with
poorly controlled type 2 diabetes, already treated with two or more oral agents who were recently
prescribed insulin. We compared responses for respondents prescribed, but never initiating,
insulin (n  69) with those dispensed insulin (n  100).
RESULTS— Subjects failing to initiate prescribed insulin commonly reported misconcep-
tions regarding insulin risk (35% believed that insulin causes blindness, renal failure, amputa-
tions, heart attacks, strokes, or early death), plans to instead work harder on behavioral goals,
sense of personal failure, low self-efficacy, injection phobia, hypoglycemia concerns, negative
impact on social life and job, inadequate health literacy, health care provider inadequately
explaining risks/benefits, and limited insulin self-management training.
CONCLUSIONS— Primary adherence for insulin may be improved through better provider
communication regarding risks, shared decision making, and insulin self-management training.
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Insulin is typically recommended forpatients with type 2 diabetes if theyhave failed to achieve adequate glyce-
mic control despite treatment with multi-
ple oral agents at maximal dose (1),
especially when -cell function declines
(2,3). Despite the known benefits of insu-
lin, many patients fail to begin insulin
treatment (4). In a previous study (5), we
followed a cohort of patients with diabe-
tes who were prescribed new glucose-
lowering medications. We observed that
4.5% of insulin-naïve patients who were
prescribed insulin never filled that pre-
scription (were primary nonadherent)
and an additional 25.5% had zero refills
(early-stage nonpersistence). Thus, one in
three insulin-naïve patients who were
prescribed insulin never became ongoing
users.
A patient’s reluctance to initiate insu-
lin has been dubbed psychological insulin
resistance (PIR) (6). Current understand-
ing of PIR is based largely on surveys of
insulin-naïve patients queried about their
hypothetical willingness to initiate insulin
(7,8). However, the reasons why patients
fail to initiate therapy after actually agree-
ing to and receiving a first prescription for
insulin have not been explored. In this
study, we evaluate barriers and attitudes
among insulin-naïve patients who had
failed to initiate newly prescribed insulin
therapy (i.e., primary nonadherent) ver-
sus those who did initiate insulin therapy
(i.e., primary adherent).
RESEARCH DESIGN AND
METHODS— Subjects for this study
of insulin adherence came from Kaiser
Permanente Northern California (Kaiser)
and Horizon Blue Cross Blue Shield of
New Jersey and were participants in the
Translating Research Into Action for Dia-
betes (TRIAD) Study (7), an ongoing
study of quality of care and self-care for
people with diabetes in managed-care set-
tings across the U.S.
We identified poorly controlled, in-
sulin-naïve and insulin-eligible type 2 di-
abetic patients receiving a new electronic
prescription for insulin. Eligibility criteria
included 1) newly prescribed insulin dur-
ing August 2007 to February 2008, 2)
Two or more diagnoses for type 2 diabetes
18 months prior to the new insulin pre-
scription, 3) no insulin use in prior 2
years, 4) already taking one oral agent at
maximum and a second oral agent at max-
imal/submaximal dose, 5) two consecu-
tive A1Cs 8% 2.5–12 months apart or
last A1C9%, and 6) two or more clinic
visits in the previous 12 months. Patients
aged85 years, with limited English pro-
ficiency, life-limiting malignancy, hos-
pice care enrollment, significant cognitive
deficits, psychiatric illness (excluding ma-
jor depression), or visual impairment lim-
iting insulin self-administration, were
excluded.
We identified a random sample of el-
igible subjects who were primary adher-
ent (at least one dispensing of insulin) and
primary nonadherent (not dispensed the
newly prescribed insulin within 60 days
of the prescribing date) from pharmacy
records. Computer-assisted telephone in-
terviews and self-administered mailed
surveys were used to collect insulin treat-
ment, provider communication, self-
management training, health literacy (8),
and depressive symptoms (9). We used
standard American Association for Public
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Opinion Research (AAPOR) algorithms
for calculating response rates (10). The
human subjects review boards in the
TRIAD translational research centers in-
volved with this study (Kaiser, the Uni-
versity of Medicine and Dentistry of New
Jersey, and Indiana University) approved
this study.
RESULTS— We mailed an invitation
letter to 195 and 186 primary nonadher-
ent and adherent subjects, respectively,
following approval of their providers. Six-
ty-nine nonadherent and 100 adherent
patients responded to the survey and are
the basis for this study. The AAPOR re-
sponse rate, which assumes that those
who could not be contacted for eligibility
confirmation had the same proportion of
eligibility as those contacted, was 60%
overall (50% in the nonadherent and 68%
in adherent group). The cooperation rate
(percent survey completion among eligi-
ble subjects we were able to reach) was
98% (100% in the nonadherent and 92%
in adherent group). None of the patient
characteristics differed significantly be-
tween adherent and nonadherent sub-
jects. Nonadherent subjects had a mean
age of 61 years and 35% were women,
49% were of a minority ethnic heritage,
37% had an income$40,000, 33% had
no college education, and 48% were re-
tired or unemployed. Adherent subjects
had a mean age of 58 years and 47% were
women, 54% were of minority ethnic her-
itage, 22% had an income $40,000,
31% had no college education, and 33%
were retired or unemployed.
Among nonadherent patients, the
most commonly cited reasons for failing
to initiate insulin included the following
reasons: The patient planned to change
health behaviors instead of starting in-
sulin (25%), injection phobia (13%),
negative impact on work (9%), con-
cerns about long-term medication use
(9%), inconvenience (6%), and not be-
lieving insulin was needed (6%). Non-
adherent patients believed that people
who require insulin “have not taken
care of themselves in the past” (47%)
and that “taking insulin can cause…”
blindness (20%), renal failure (32%),
amputations (15%), heart attacks or
strokes (19%), and early death (19%).
In all, 35% of the insulin-nonadherent
group reported that they believed insu-
lin causes harm (at least one of the pos-
sible complications listed above).
Compared with adherent patients,
nonadherent patients expressed signifi-
cantly more concern about their inability
to adjust insulin dosage, the impact on
social life and work, injection pain, and
side effects, particularly hypoglycemia
(Table 1). Significantly more nonadher-
ent patients reported problems learning
about their medical condition because of
difficulty understanding written informa-
tion (inadequate health literacy) and
claimed providers failed to adequately ex-
plain insulin’s risk and benefits. Substan-
tially fewer nonadherent patients reported
receiving insulin self-management training
from their doctor, nurse, health educator,
or a class.
CONCLUSIONS— Among poorly
controlled patients with type 2 diabetes
newly prescribed insulin, the major pre-
dictors of insulin nonadherence included
plans to improve health behaviors in lieu
of starting insulin, negative impact on so-
cial and work life, injection phobia, and
concerns about side effects or hypoglyce-
mia. Nonadherent patients often blamed
themselves, believing prior poor self-
management caused the current need for
insulin and erroneously conceptualized
insulin as itself the cause of future com-
plications. These patient-level findings
are consistent with previous studies of at-
titudes about insulin (11,12).
Not previously reported is our find-
ing that nonadherent patients frequently
felt their provider had not adequately ex-
plained the risks and benefits of insulin.
The importance of provider communica-
tion is underscored by the association be-
tween insulin initiation and health
literacy (13). Primary nonadherence
Table 1—Comparisons of survey responses for primary nonadherent and adherent patients
newly prescribed insulin*
Nonadherent Adherent
Stated moderate/extreme concerns (versus not at all or a
little concerned) regarding:
The cost of insulin shots 12/51 (24) 22/82 (27)
How insulin shots might restrict your activities or “hold
back” your lifestyle 20/54 (37) 20/82 (24)
The additional burden associated with home monitoring
of blood sugar 15/59 (25) 19/82 (23)
Difficulty giving insulin due to things like poor eyesight,
shakiness, or arthritis 23/55 (42) 24/81 (30)
Your ability to make dose adjustments† 22/54 (41) 10/82 (12)
How insulin shots may negatively impact your social life† 21/56 (38) 15/82 (18)
A negative impact on your job (if you work outside the
home)† 15/45 (33) 6/72 (8)
The insulin shots being painful† 17/56 (30) 12/82 (15)
Possible side effects of giving yourself shots† 24/55 (44) 10/81 (12)
Insulin shots causing you to have low blood glucose† 22/51 (43) 13/81 (16)
Patient-provider interactions and communication
Never or only sometimes (versus usually or always) felt
confidence or trust in personal physician that manages
diabetes 11/68 (16) 11/97 (11)
Moderately or extremely difficult (versus not at all
difficult or a little difficult) to talk with doctor about
concerns about diabetes medication or insulin 9/66 (14) 10/100 (10)
Risks and benefits were not very well or not well at all
(versus somewhat well or very well) explained† 37/67 (55) 37/96 (39)
Inadequate health literacy: sometimes, often, or always
(versus never or rarely); have problems learning about
medical condition because of difficulty understanding
written information (not including problems due to
poor vision)† 35/69 (51) 30/99 (30)
How was the insulin self-management training provided
Doctor trained† 1/66 (2) 13/77 (17)
Insulin self-management class† 5/66 (8) 31/77 (40)
Nurse trained† 4/66 (6) 33/77 (43)
Data are n/N (%). *N takes into account missing responses. †Significant contrasts (P  0.05).
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likely also reflects inadequate shared de-
cision making or lack of self-management
training. Interventions for PIR need to ad-
dress both provider- and system-level fac-
tors (14–16).
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